Pivotal Trials Are Cheaper For Unmet Needs And Orphan Drugs, JAMA Study Finds
Executive Summary
Analysis of clinical trial costs for CDER’s 2015-2016 novel therapeutic approvals finds pivotal studies are most expensive when a new agent has a similar benefit to already marketed products with well-established clinical profiles.
You may also be interested in...
US FDA's Gottlieb Touts 'Seamless' Clinical Trials, Worries About Second-To-Market Products
Commissioner tells House hearing that agency study found troubling drop in innovative competition; clinical trial reform, including encouraging surrogate markers, could speed development of products that may create pricing pressure on brands.
Real World Data Helping To Drive Rise Of Novartis' Entresto
Patients with heart failure on Entresto say they have fewer symptoms and greater quality of life, according to a registry study and Novartis is hoping that this and other real world data will propel the drug towards its peak sales target of $5bn.
Savaysa Shows The Good And Bad Of Being Late In Class
As Daiichi’s experience suggests, sponsors of later-in-class products may face unfavorable efficacy comparisons to their earlier-approved brethren and challenges in qualifying for a priority review; however, risk management obligations may be less burdensome than for first-in-class products.